Searched for
DRUG PRICING POLICY
How many Americans can afford high-quality healthcare? A new poll finds the number has fallenAmericans face growing challenges affording healthcare. New data reveals a significant drop in those able to manage medical costs and acces...- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities extended gains for a third straight session, with Sensex and Nifty rising on optimism over the Iran-US peace framework and ...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- The old health insurance model sees hospitalisation as an inconvenience, says Narayana Health's Viren Prasad Shetty; bets on managed care modelIt has been close to two years since Narayana Health’s wholly owned subsidiary, Narayana Health Insurance—which has adopted a ‘managed heal...
- Ahead of Market: 10 things that will decide stock market action on MondayMarkets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...
- From white knuckles to open barbs, Trump, Macron bring rocky history to G7 summitThe bond between US President Donald Trump and French President Emmanuel Macron began with a firm handshake but has since seen open disagre...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Japanese investors are looking beyond China... India is key alternative: Tsutomu Takemura, Senior MD, NomuraIndia is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Market Trading Guide: Akums Drugs among 4 stock recommendations for ThursdayDomestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain ...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
- US stocks today: US market gains as semiconductor stocks rebound, Middle East tensions easeMajor Wall Street indexes saw a strong rebound. This recovery was driven by gains in chip stocks. Signs of de-escalation in Middle East ten...
- Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supplyUzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
- Infosys, Tech Mahindra, TCS and other IT stocks jump up to 5%. What’s driving the rally?Indian IT stocks rose sharply on Monday, lifting the Nifty IT index nearly 3%, as investors reassessed AI-related fears, attracted by attra...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- PSU closure: Govt sets in motion new move after years wasted in stop-start processThe Centre is pushing ministries to accelerate the closure of unprofitable state-owned companies. Progress has been slow despite a policy a...
- Despite Trump's pressure, Cuba may not turn out like VenezuelaThe U.S. is increasing pressure on Cuba, but unlike Venezuela, the island nation lacks a clear opposition leader or succession plan. Cuba's...
Load More
